Targets and strategies for T-cell based vaccines in patients with B-cell chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 47, Issue 10, 2006, Pages 2028-2036

  Giannopoulos, Krzysztof ^a   Schmitt, Michael ^b  

^a UNIVERSITY OF ULM   (Germany)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

B cellchronic lymphocytic leukemia (B CLL); Dendritic cells (DCs); Leukemia associated antigens (LAAs); T cell based vaccines; Tumor associated antigens (TAAs)

Indexed keywords

ADJUVANT; FIBROMODULIN; HYALURONIC ACID BINDING PROTEIN; IMMUNOGLOBULIN IDIOTYPE; INTERLEUKIN 15; LAMININ RECEPTOR; LEUKEMIA ANTIGEN; ONCOFETAL ANTIGEN; PROTEIN MDM2; RECEPTOR PROTEIN; SURVIVIN; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; B CELL LEUKEMIA; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DENDRITIC CELL; DISEASE COURSE; DRUG TARGETING; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; TUMOR CELL;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LEUKEMIA, B-CELL, CHRONIC; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MODELS, BIOLOGICAL; MONOCYTES; T-LYMPHOCYTES;

EID: 33750438808     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600709721     Document Type: Review

References (79)

1. Keating, M and Chiorazzi, N and Messmer, B and Damle, R and Allen, S and Rai, K and (2005) Biology and treatment of chronic lymphocytic leukemia Hematology, pp. 153-175. ASH Educational Program
2. Hallek, M. (2005) Chronic lymphocytic leukemia (CLL): First-line treatment Hematology, pp. 285-291. ASH Educational Program
3. Dighiero, G. (1997) Chronic lymphocytic leukemia treatment Hematol Cell Ther, 39, pp. 31-40.
4. Ribera, J and Vinolas, N and Urbano-Ispizua, A and Gallart, T and Montserrat, E and Rozman, C. (1987) 'Spontaneous' complete remissions in chronic lymphocytic leukemia: Report of three cases and review of the literature Blood Cells, 12, pp. 471-483.
5. Ziegler-Heitbrock, H and Schlag, R and Flieger, D and Thiel, E. (1989) Favorable response of early stage B CLL patients to treatment with IFN-alpha 2 Blood, 73, pp. 1426-1430.
6. Ritgen, M and Stilgenbauer, S and von Neuhoff, N and Humpe, A and Bruggemann, M and Pott, C and (2004) Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: Implications of minimal residual disease measurement with quantitative PCR Blood, 104, pp. 2600-2602.
7. Gitelson, E and Hammond, C and Mena, J and Lorenzo, M and Buckstein, R and Berinstein, N and (2003) Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines Clin Cancer Res, 9, pp. 1656-1665.
8. Goddard, R and Prentice, A and Copplestone, J and Kaminski, E. (2001) Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate Clin Exp Immunol, 126, pp. 16-28.
9. Tsiodras, S and Samonis, G and Keating, M and Kontoyiannis, D. (2000) Infection and immunity in chronic lymphocytic leukemia Mayo Clin Proc, 75, pp. 1039-1054.
10. Scrivener, S and Goddard, R and Kaminski, E and Prentice, A. (2003) Abnormal T-cell function in B-cell chronic lymphocytic leukaemia Leuk Lymphoma, 44, pp. 383-389.
11. Orsini, E and Guarini, A and Chiaretti, S and Mauro, F and Foa, R. (2003) The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response Cancer Res, 63, pp. 4497-4506.
12. Ravandi, F and O'Brien, S. (2006) Immune defects in patients with chronic lymphocytic leukemia Cancer Immunol Immunother, 55, pp. 197-209.
13. Griffiths, H and Lea, J and Bunch, C and Lee, M and Chapel, H. (1992) Predictors of infection in chronic lymphocytic leukaemia (CLL) Clin Exp Immunol, 89, pp. 374-377.
14. Rozman, C and Montserrat, E and Vinolas, N. (1988) Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance Cancer, 61, pp. 279-283.
15. Kunicka, J and Platsoucas, C. (1988) Leukaemic B cells from patients with chronic lymphocytic leukaemia suppress immunoglobulin production by lymphocytes from normal donors Scand J Immunol, 28, pp. 1-10.
16. Kurec, A and Davey, F. (1987) Impaired synthesis of immunoglobulin in patients with chronic lymphocytic leukemia Am J Hematol 25, pp. 131-142.
17. Herrmann, F and Sieber, G and Chen, Z and Enders, B and Komischke, B and Ruhl, H. (1983) Further evidence for T cell abnormalities in chronic lymphocytic leukaemia of the B cell type Clin Exp Immunol, 53, pp. 109-114.
18. Steinman, R and Hawiger, D and Nussenzweig, M. (2003) Tolerogenic dendritic cells Annu Rev Immunol, 21, pp. 685-711.
19. Gilliet, M and Liu, Y. (2002) Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells J Exp Med, 195, pp. 695-704.
20. Vuillier, F and Maloum, K and Thomas, E and Jouanne, C and Dighiero, G and Scott-Algara, D. (2001) Functional monocyte-derived dendritic cells can be generated in chronic lymphocytic leukaemia Br J Haematol, 115, pp. 831-844.
21. Goddard, R and Prentice, A and Copplestone, J and Kaminski, E. (2003) In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids Clin Exp Immunol, 131, pp. 82-89.
22. Goddard, R and Prentice, A and Copplestone, J and Kaminski, E. (2001) Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate Clin Exp Immunol, 126, pp. 16-28.
23. Norris, D and Weston, W and Tubergen, D and Rose, B and Odom, L. (1980) Monocyte chemotaxis in leukemia patients J Lab Clin Med, 95, pp. 609-615.
24. Fernandez, R and Lee, S and Fernandez, L and Pope, B and Rozee, K. (1986) Production of interferon by peripheral blood mononuclear cells from normal individuals and patients with chronic lymphocytic leukemia J Interferon Res, 6, pp. 573-580.
25. Flieger, D and Emmerich, B and Meyer, N and Riethmuller, G and Ziegler-Heitbrock, H. (1990) Deficient production of tumor necrosis factor by peripheral-blood monocytes in chronic lymphocytic leukemia Int J Cancer, 45, pp. 280-286.
26. Tsukada, N and Burger, J and Zvaifler, N and Kipps, T. (2002) Distinctive features of 'nurselike' cells that differentiate in the context of chronic lymphocytic leukemia Blood, 99, pp. 1030-1037.
27. Foa, R and Fierro, M and Lusso, P and Raspadori, D and Ferrando, M and Matera, L and (1986) Reduced natural killer T-cells in B-cell chronic lymphocytic leukaemia identified by three monoclonal antibodies: Leu-11, A10, AB8.28 Br J Haematol, 62, pp. 151-154.
28. Kokhaei, P and Choudhury, A and Mahdian, R and Lundin, J and Moshfegh, A and Osterborg, A and Mellstedt, H. (2004) Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL Leukemia, 18, pp. 1810-1815.
29. Kokhaei, P and Rezvany, M and Virving, L and Choudhury, A and Rabbani, H and Osterborg, A and Mellstedt, H. (2003) Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL Leukemia, 17, pp. 894-899.
30. Palena, C and Foon, K and Panicali, D and Yafal, A and Chinsangaram, J and Hodge, J and (2005) Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): Enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules Blood, 106, pp. 3515-3523.
31. Decker, T and Schneller, F and Sparwasser, T and Tretter, T and Lipford, G and Wagner, H and Peschel, C. (2000) Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells Blood, 95, pp. 999-1006.
32. Speiser, D and Lienard, D and Rufer, N and Rubio-Godoy, V and Rimoldi, D and Lejeune, F and (2005) Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909 J Clin Invest, 115, pp. 739-746.
33. Dicker, F and Kater, A and Fukuda, T and Kipps, T. (2005) Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells Blood, 105, pp. 3193-3198.
34. Wierda, W and Cantwell, M and Woods, S and Rassenti, L and Prussak, C and Kipps, T. (2000) CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia Blood, 96, pp. 2917-2924.
35. Marks, D and Lush, R and Cavenagh, J and Milligan, D and Schey, S and Parker, A and (2002) The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation Blood, 100, pp. 3108-3114.
36. Kollgaard, T and Petersen, S and Hadrup, S and Masmas, T and Seremet, T and Andersen, M and (2005) Evidence for involvement of clonally expanded CD8+ T cells in anticancer immune responses in CLL patients following nonmyeloablative conditioning and hematopoietic cell transplantation Leukemia, 19, pp. 2273-2280.
37. Greiner, J and Li, L and Ringhoffer, M and Barth, T and Giannopoulos, K and Guillaume, P and (2005) Identification and characterization of epitopes of the receptor for hyaluronic acid mediated motility (RHAMM/ CD168) recognized by CD8 positive T cells of HLA-A2 positive patients with acute myeloid leukemia Blood, 106, pp. 938-945.
38. Trojan, A and Schultze, J and Witzens, M and Vonderheide, R and Ladetto, M and Donovan, J and Gribben, J. (2000) Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies Nat Med, 6, pp. 667-672.
39. Harig, S and Witzens, M and Krackhardt, A and Trojan, A and Barrett, P and Broderick, R and (2001) Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues Blood, 98, pp. 2999-3005.
40. Greiner, J and Ringhoffer, M and Taniguchi, M and Schmitt, A and Kirchner, D and Krähn, G and (2002) RHAMM is a new immunogenic tumor-associated antigen overexpressed in acute and chronic myeloid leukemia Exp J Hematol, 30, pp. 1029-1035.
41. Greiner, J and Ringhoffer, M and Taniguchi, M and Schmitt, A and Döhner, H and Schmitt, M. (2003) Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia (AML/CML) Int J Cancer, 106, pp. 224-231.
42. Craine, M and Belch, A and Mant, M and Pilarski, L. (1999) Overexpression of the receptor for hyaluronan-mediated motolity (RHAMM) characterizes the malignant clones in multiple myeloma: Identification of three distinct RHAMM variants Blood, 93, pp. 1684-1696.
43. Assmann, V and Marshal, J and Fieber, C and Hofmann, M and Hart, I. (1998) The human hyaluronan receptor RHAMM is expressed as an intracellular protein in breast cancer cells J Cell Sci, 111, pp. 1685-1694.
44. Giannopoulos, K and Hus, I and Li, L and Bojarska-Junak, A and Greiner, J and Roliński, J and (2005) The receptor for hyaluronic acid mediated motility (RHAMM/CD168) is a potential target for immunotherapy of patients with B-cell chronic lymphocytic leukemia Blood, 106, pp. 20a.
45. Giannopoulos, K and Li, L and Bojarska-Junak, A and Roliński, J and Dmoszyńska, A and (2006) Expression of RHAMM/CD168 and other tumor associated antigens in patients with B-cell chronic lymphocytic leukemia Int J Oncol, 29, pp. 95-103.
46. Hus, I and Rolinski, J and Tabarkiewicz, J and Wojas, K and Bojarska-Junak, A and Greiner, J and (2005) Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia Leukemia, 19, pp. 1621-1627.
47. Mayr, C and Bund, D and Schlee, M and Bamberger, M and Kofler, D and Hallek, M and Wendtner, C. (2006) MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8(+) autologous T lymphocytes Exp Hematol, 34, pp. 44-53.
48. Levav-Cohen, Y and Haupt, S and Haupt, Y. (2005) Mdm2 in growth signaling and cancer Growth Factors, 23(3), pp. 183-192.
49. Zhang, Z and Zhang, R. (2005) p53-independent activities of MDM2 and their relevance to cancer therapy Curr Cancer Drug Targets, 5, pp. 9-20.
50. Onel, K and Cordon-Cardo, C. (2004) MDM2 and prognosis Mol Cancer Res, 2, pp. 1-8.
51. Klein, C and Vassilev, L. (2004) Targeting the p53-MDM2 interaction to treat cancer Br J Cancer, 91(8), pp. 1415-1419.
52. Müller, M and Tsakou, G and Grunebach, F and Schmidt, S and Brossart, P. (2004) Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells Blood, 103, pp. 1763-1769.
53. Ambrosini, G and Adida, C and Altieri, D. (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma Nat Med, 3, pp. 917-921.
54. Gordan, J and Vonderheide, R. (2002) Universal tumor antigens as targets for immunotherapy Cytotherapy, 4, pp. 317-327.
55. Zeis, M and Siegel, S and Wagner, A and Schmitz, M and Marget, M and Kuhl-Burmeister, R and (2003) Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells J Immunol, 170, pp. 5391-5397.
56. Granziero, L and Ghia, P and Circosta, P and Gottardi, D and Strola, G and Geuna, M and (2001) Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia Blood, 97, pp. 2777-2783.
57. van Kooten, C and Banchereau, J. (2000) CD40-CD40 ligand J Leukoc Biol, 67, pp. 2-17.
58. Buhmann, R and Nolte, A and Westhaus, D and Emmerich, B and Hallek, M. (1999) CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: Stimulation of allogeneic versus autologous T cells generates different types of effector cells Blood, 93, pp. 1992-2002.
59. Krackhardt, A and Harig, S and Witzens, M and Broderick, R and Barrett, P and Gribben, J. (2002) T-cell responses against chronic lymphocytic leukemia cells: Implications for immunotherapy Blood, 100, pp. 167-173.
60. Schmidt, S and Schag, K and Muller, M and Weck, M and Appel, S and Kanz, L and (2003) Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood, 102, pp. 571-576.
61. Reker, S and Becker, J and Svane, I and Ralfkiaer, E and Straten, P and Andersen, M. (2004) HLA-B35-restricted immune responses against survivin in cancer patients Int J Cancer, 108, pp. 937-941.
62. Caligaris-Cappio, F. (1996) B-Chronic lymphatic leukemia: A malignancy of anti-self B cells Blood, 87, pp. 2615-2620.
63. Klein, U and Tu, Y and Stolovitzky, G and Mattioli, M and Cattoretti, G and Husson, H and (2001) Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells J Exp Med 194, pp. 1625-1638.
64. Mayr, C and bund, D and Schlee, M and Moosmann, A and Kofler, D and Hallek, M and Wendtner, C. (2005) Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) which allows expansion of specific CD8+ autologous T lymphocytes Blood, 105, pp. 1566-1573.
65. Hedbom, E and Heinegard, D. (1993) Binding of fibromodulin and decorin to separate sites on fibrillar collagens J Biol Chem, 268, pp. 27307-27312.
66. Mikaelsson, E and Danesh-Manesh, A and Luppert, A and Jeddi-Tehrani, M and Rezvany, M and Sharifian, R and (2005) Fibromodulin, an extracellular matrix protein: Characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma Blood, 105, pp. 4828-4835.
67. Mayr, C and Kofler, D and Buning, H and Bund, D and Hallek, M and Wendtner, C. (2005) Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells Blood, 106, pp. 3223-3226.
68. Weinschenk, T and Gouttefangeas, C and Schirle, M and Obermayr, F and Walter, S and Schoor, O and (2002) Integrated functional genomics approach for the design of patient-individual antitumor vaccines Cancer Res, 62, pp. 5818-5827.
69. Schmidt, S and Schag, K and Muller, M and Weinschenk, T and Appel, S and Schoor, O and (2004) Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis Cancer Res, 64, pp. 1164-1170.
70. Siegel, S and Wagner, A and Kabelitz, D and Marget, M and Coggin, J, Jr and Barsoum, A and (2003) Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies Blood, 102, pp. 4416-4423.
71. Su, Z and Dannull, J and Heiser, A and Yancey, D and Pruitt, S and Madden, J and (2003) Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells Cancer Res, 63, pp. 2127-2133.
72. Rohrer, J and Barsoum, A and Dyess, D and Tucker, J and Coggin, J, Jr. (1999) Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes J Immunol, 162, pp. 6880-6892.
73. Castronovo, V and Van Den Brule, F and Jackers, P and Clausse, N and Liu, F and Gillet, C and Sobel, M. (1996) Decreased expression of galectin-3 is associated with progression of human breast cancer J Pathol, 179, pp. 43-48.
74. Krackhardt, A and Witzens, M and Harig, S and Hodi, F and Zauls, A and Chessia, M and (2002) Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX Blood, 100, pp. 2123-2131.
75. Stockinger, B. (1999) T lymphocyte tolerance: From thymic deletion to peripheral control mechanisms Adv Immunol, 71, pp. 229-265.
76. Greiner, J and Giannopoulos, K and Li, L and Liebisch, P and Wendl, C and Chen, J and (2005) RHAMM/CD168-R3 peptide vaccination of HLA-A2+ patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM). ASH Annual meeting, Atlanta Blood, 106, pp. 2781. (Abstract)
77. Banchereau, J and Palucka, A. (2005) Dendritic cells as therapeutic vaccines against cancer Nat Rev Immunol, 5, pp. 296-306.
78. Spaner, D and Hammond, C and Mena, J and Foden, C and Deabreu, A. (2005) A phase I/II trial of oxidized autologous tumor vaccines during the "watch and wait" phase of chronic lymphocytic leukemia Cancer Immunol Immunother, 54, pp. 635-646.
79. Porter, D and Levine, B and Bunin, N and Stadtmauer, E and Luger, S and Goldstein, S and (2006) A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation Blood, 107, pp. 1325-1331.